Doctor profile · Federal record
Dr. Sayuri Cheruvu, M.B.,B.S
Medical Oncology Physician (CMS: Hematology/Oncology) · Mishawaka, IN
- NPI 1134357213
- Accepts Medicare
- MIPS 78.2 / 100 · 2023
- 20 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
Operates at 2 locations .
- Primary practice
-
5340 Holy Cross Pkwy
Mishawaka, IN 465451470
(574) 237-1328
fax (574) 237-1348 - Additional location
-
2400 17Th St
Columbus, IN 472015351
(812) 376-5550 - Mailing address
-
Po Box 746092
Atlanta, GA 303746092
Credentials & registration
- NPI registered
- June 2009 — 17 yrs on file
- Profile last updated
- March 26, 2026
- Year of graduation
- 2006 — 20 yrs since
- Specialty taxonomy
- 207RX0202X — NUCC code
- State license (1)
- Indiana #01080364A
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1134357213. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
121,970
Distinct HCPCS
10
Medicare allowed
$1,193,494
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 23,060 | 29 | $3 | |
Q5101 |
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 21,420 | 19 | $0 | |
Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 15,282 | 125 | $0 | |
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 13,260 | 18 | $0 | |
J9263 |
Injection, oxaliplatin, 0.5 mg | 11,500 | 11 | $0 | |
J0897 |
Injection, denosumab, 1 mg | 8,640 | 52 | $23 | |
J9271 |
Injection, pembrolizumab, 1 mg | 7,800 | 19 | $54 | |
J9267 |
Injection, paclitaxel, 1 mg | 4,476 | 14 | $0 | |
J1100 |
Injection, dexamethasone sodium phosphate, 1 mg | 3,374 | 123 | $0 | |
J0185 |
Injection, aprepitant, 1 mg | 3,120 | 13 | $2 |
In context: peer comparison
Among 2 peers in Mishawaka Medical Oncology Physician, average services per provider: 2,538. This provider delivers 48× the peer median.Open Payments
Industry payments received
All-time total
$312
Transactions
16
Manufacturers
12
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $44.33 | |
| Genentech USA, INC. | 2 | $36.56 | |
| AstraZeneca Pharmaceuticals Lp | 2 | $36.54 | |
| Pfizer INC. | 2 | $34.83 | |
| E.R. Squibb & Sons, L.L.C. | 1 | $27.30 | |
| Emd Serono, INC. | 1 | $23.17 | |
| Pharmacosmos Therapeutics INC. | 1 | $22.36 | |
| GlaxoSmithKline, LLC. | 1 | $21.34 | |
| Aveo Pharmaceuticals, INC. | 1 | $20.00 | |
| Celgene Corporation | 1 | $16.45 | |
| Acrotech Biopharma INC. | 1 | $14.69 | |
| Tempus Ai, INC | 1 | $14.33 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,403
Patients
421
Total drug cost
$891,188
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Anastrozole | Generic | 286 | 80 | $7,973 |
| Tamoxifen Citrate | Generic | 164 | 43 | $4,980 |
| Prednisone | Generic | 127 | 42 | $1,227 |
| Eliquis (Apixaban) | Brand | 109 | 26 | $79,296 |
| Prochlorperazine Maleate | Generic | 97 | 61 | $1,744 |
| Letrozole | Generic | 88 | 29 | $4,880 |
| Gabapentin | Generic | 84 | 16 | $807 |
| Hydroxyurea | Generic | 84 | 20 | $3,309 |
| Xarelto (Rivaroxaban) | Brand | 64 | 16 | $54,511 |
| Pantoprazole Sodium | Generic | 63 | 29 | $905 |
Frequently asked questions
What is Dr. Sayuri Cheruvu's medical specialty?
Dr. Sayuri Cheruvu practices Medical Oncology Physician in Mishawaka, IN.
Where does Dr. Sayuri Cheruvu practice?
Dr. Sayuri Cheruvu practices at 5340 Holy Cross Pkwy, Mishawaka, IN 465451470. Office phone: 5742371328.
What is Dr. Sayuri Cheruvu's NPI?
Dr. Sayuri Cheruvu's National Provider Identifier (NPI) is 1134357213, issued by NPPES.
Does Dr. Sayuri Cheruvu accept Medicare assignment?
Yes. Dr. Sayuri Cheruvu accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Sayuri Cheruvu commonly perform?
Top Medicare-reported procedures in 2023: Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS J0881); Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS Q5101); Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS Q9967). Source: CMS Medicare Physician & Other Practitioners file.